Interestingly, the gp-96 HSP non-covalently binds to tumor antigens present in the patient's own tumor forming an immunogenic complex that is capable of activating CTL, but neither the gp-96, nor the tumor antigen is immunogenic on its own [37,38]. This evidence concerns the gene HSP90B2P and neoplasm.